Bellevue Life Sciences Acquisition Corp. Unit
BLACU
BLACU was delisted on the 14th of February, 2025.
3 hedge funds and large institutions have $50.8K invested in Bellevue Life Sciences Acquisition Corp. Unit in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
26% more capital invested
Capital invested by funds: $40.4K → $50.8K (+$10.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.5K |
| 2 |
CS
Clear Street
New York
|
+$5.14K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $45.8K | +$5.14K | +467 | +13% |
|
|
2
UBS Group
Zurich,
Switzerland
| $4.92K | +$5.5K | +500 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $110 | – | – | – |
|
BLACU Hedge Fund Activity: Q3 2024 in Review
3 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Unit (BLACU) for Q3 2024, worth a combined $50.8K — up 26% from $40.4K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BLACU positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $5.5K.
- 3 institutional investors held Bellevue Life Sciences Acquisition Corp. Unit (BLACU) as of Q3 2024, up from 2 in Q2 2024.
- Funds reported $50.8K of Bellevue Life Sciences Acquisition Corp. Unit stock for Q3 2024, up 26% quarter-over-quarter.
- 1 fund opened new Bellevue Life Sciences Acquisition Corp. Unit positions in Q3 2024 and 0 closed out, a net change of +1 holder.
- The largest Bellevue Life Sciences Acquisition Corp. Unit buyer in Q3 2024 was UBS Group, an estimated $5.5K added.
Based on aggregated 13F filings for Q3 2024.